Sponsrat Sponsrat

OssDsign has carried out a directed share issue raising proceeds of approximately SEK 65 million to finance the Sirakoss acquisition

The Board of Directors of OssDsign AB (publ) (”OssDsign” or the ”Company”) has, as communicated in the Company’s press release earlier today, resolved to carry out a directed share issue of 4,433,292 shares (corresponding to 25 percent of the total number of outstanding shares and votes in the Company) at a subscription price of SEK 14.70 per share (the “Directed Issue”). Due to the Directed Issue being heavily over-subscribed by a large number of Swedish and international investors, the gross proceeds in the Directed Issue were increased from the SEK 55 million indicated in the Company’s press release earlier today. Through the Directed Issue, OssDsign will receive proceeds amounting to approximately SEK 65 million before transaction costs. The proceeds from the Directed Issue will be used to finance the acquisition of Sirakoss, a company specialized in bone graft substitute (the “Acquisition”), as announced by the Company earlier today.

Uppdaterad 2020-11-03
Publicerad 2020-11-03

Summary of the Directed Issue

The Board of Directors of OssDsign has, in accordance with the issue authorization granted by the Annual General Meeting on May 20, 2020, and as indicated in the press release of the Company earlier today, resolved on a directed issue of 4,433,292 shares at a subscription price of SEK 14.70 per share, consequently raising gross proceeds of approximately SEK 65 million. The subscription price in the Directed Issue has been determined through an accelerated book building, why it is the assessment of the Board of Directors that the subscription price accurately reflects current market conditions and demand.

The subscription price of SEK 14.70 per share corresponds to a discount of approximately 10 percent in relation to the closing price on Nasdaq First North Growth Market on November 3, 2020. A large number of Swedish and international investors participated in the Directed Issue.

The reason for deviating from the shareholders’ preferential right is to carry out a capital raise for the financing of the Acquisition. For additional information on the Acquisition, see the separate press release with headline "OssDsign expands to the USD 4 billion bone graft market by acquiring Scottish company Sirakoss" that was published today.

The Directed Issue entails a dilution of 20 percent of the number of shares and votes in the Company. Through the Directed Issue, the number of outstanding shares and votes will increase by 4,433,292 from 17,733,168 to 22,166,460. The share capital will increase by SEK 277,080.75 from SEK 1,108,323.00 to SEK 1,385,403.75.

In connection with the Directed Issue, members of the Board of Directors of OssDsign and management representatives of OssDsign have agreed not to sell any shares in OssDsign for a period of 90 days after the announcement of the outcome of the Directed Issue, subject to customary exceptions.


ABG Sundal Collier has acted as sole global coordinator and joint bookrunner and Erik Penser Bank has acted as joint bookrunner in connection with the Directed Issue. Setterwalls Advokatbyrå acted as legal adviser to the Company in connection with the Directed Issue.

Certified Adviser
Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.

For more information, please contact:
Morten Henneveld, CEO, OssDsign AB
Phone: +46 73 382 43 90, email: morten.henneveld@ossdsign.com

This is information that OssDsign AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 21:15 CEST on November 3, 2020.

About OssDsign

OssDsign is a Swedish medtech company dedicated to creating regenerative implants for improved healing of bone defects. OssDsign provides neurosurgeons and reconstructive plastic surgeons around the world with an expanding range of innovative implant solutions for improved patient outcomes. OssDsign’s technology is the result of collaboration between clinical researchers at the Karolinska University Hospital, Stockholm, and material science experts at the Ångström Laboratory at Uppsala University.For more information, please visit www.ossdsign.com.

Important information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in OssDsign in any jurisdiction, neither from OssDsign nor from anyone else.

Any investment decision in connection with the Issue must be made on the basis of all publicly available information relating to the Company and the Company’s shares. Such information has not been independently verified by the sole global coordinator and joint bookrunners. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied or distributed, directly or indirectly, in whole or in part, to Australia, Canada, Japan or the United States of America or in any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. OssDsign has not authorized any offer to the public of shares or rights in any member state of the EEA and no prospectus has been or will be prepared in connection with the Directed Issue. In any EEA Member State and the United Kingdom, this communication is only addressed to and is only directed at qualified investors in that Member State or in the United Kingdom within the meaning of the Prospectus Regulation.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this document and should not act or rely on it.

Information to distributors

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the shares in OssDsign have been subject to a product approval process, which has determined that the shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, distributors should note that: the price of the shares may decline and investors could lose all or part of their investment; the shares offer no guaranteed income and no capital protection; and an investment in the shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Offer. Furthermore, it is noted that, notwithstanding the Target Market Assessment, the Joint Bookrunners will only procure investors who meet the criteria of professional clients and eligible counterparties.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in OssDsign.

Each distributor is responsible for undertaking its own target market assessment in respect of the shares in OssDsign and determining appropriate distribution channels.

Forward-looking statements

This press release contains forward-looking statements that reflect the Company’s intentions, beliefs, or current expectations about and targets for the Company’s future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as “believe”, “expect”, “anticipate”, “intend”, “may”, “plan”, “estimate”, “will”, “should”, “could”, “aim” or “might”, or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this press release or any obligation to update or revise the statements in this press release to reflect subsequent events. Undue reliance should not be placed on the forward-looking statements in this press release. The information, opinions and forward-looking statements contained in this press release speak only as at its date and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release.